摘要
目的:研究Ki-67在乳腺浸润性导管癌中的表达及标准意义。方法:本文将收治时间在2018年6月-2020年5月的38例乳腺浸润性导管癌患者作为研究对象,采用已知阳性的组织切片作为阳性对照,采用PBS代替一抗作为阴性对照,分析患者乳腺浸润性导管癌组织Ki-67的表达,研究和临床病理特征之间的关系。结果:Ki-67表达位于患者细胞核,具有较高的表达率,Ki-67高表达和肿瘤组织学分级、淋巴转移相关,随着肿瘤体积增大Ki-67表达呈现增高趋势。且ER阴性、PR阴性的患者,Ki-67为高表达。结论:Ki-67在乳腺浸润性导管癌中具有显著的意义。
Objective: To study the expression and standard significance of Ki-67 in breast invasive ductal carcinoma.Methods: 38 patients with breast invasive ductal carcinoma treated from June 2018 to May 2020 were taken as the research objects, the known positive tissue sections were used as the positive control, and PBS was used instead of 1antibody as the negative control to analyze the breast invasive ductal carcinoma. The expression of Ki-67 in cancer tissues was analyzed and the relationship between clinicopathological features was studied. Results: The expression of Ki-67 was located in the nucleus of patients with high expression rate. The high expression of Ki-67 was related to tumor histological grade and lymphatic metastasis. The expression of Ki-67 increased with the increase of tumor volume. Ki-67 was highly expressed in patients with ER negative and PR negative. Conclusion: Ki-67 has significant significance in breast invasive ductal carcinoma.
作者
陈凤雯
CHEN Feng-wen(Shanwei Yihui Foundation Hospital)
出处
《中国标准化》
2022年第20期279-281,共3页
China Standardization